Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Henan Lvyuan Pharmaceutical Co., Ltd.
WARNING LETTER
•Henan Lvyuan Pharmaceutical Co., Ltd.•September 26, 2025

Henan Lvyuan Pharmaceutical Co., Ltd. – FDA Warning Letter, Sep 26, 2025

Record Details

Henan Lvyuan Pharmaceutical Co. Ltd., based in Henan, China, received an FDA warning letter following an inspection conducted from September 22 to 26, 2025. The agency identified significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs). Under the Federal Food, Drug, and Cosmetic Act, these violations classify the company"s products as adulterated. Primary concerns involve the failure to maintain buildings and equipment properly. Inspectors observed extensive corrosion on manufacturing tanks and numerous water leaks in warehouses, production, and packaging areas. Such conditions create substantial risks for microbial contamination and chemical degradation of APIs. Additionally, the company failed to maintain adequate master production and control records. Specific batch records lacked essential processing details, such as time limits and ingredient weights, making it impossible to ensure consistent product quality. The FDA also highlighted potential cross-contamination risks due to inadequate separation between different manufacturing operations. While the company responded to initial findings, the FDA deemed the response insufficient. Consequently, Henan Lvyuan must now provide a comprehensive risk assessment for all drug lots currently distributed in the United States. This must include potential customer notifications or product recalls if quality issues are found. The company is also required to implement a robust preventive maintenance program and undergo an independent, global review of its production processes and documentation. The FDA has granted the company 15 working days to respond with a detailed plan for corrective actions. Failure to address these deficiencies may result in the FDA refusing entry of the company"s products into the United States or withholding approval for new drug applications.

Company
Henan Lvyuan Pharmaceutical Co., Ltd.
Inspection date
September 26, 2025
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • He Jingyin
  • Jamie Dion (Consumer Safety Officer)
  • Francis Godwin (Director)
  • Dillard H. Woody Jr. (Acting Director)
View Company Profile

ID · 11666e1b-1d75-469a-9896-272ddee87a1e

Violation Codes4
FD&C Act 801(a)(3)FD&C Act 501(a)(2)(B)21 U.S.C. 381(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Henan Lvyuan Pharmaceutical Co., Ltd.
  • 483 - 2025-09-26September 26, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Henan Lvyuan Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.